Delcath Systems Inc
NASDAQ:DCTH
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
US |
Delcath Systems Inc
NASDAQ:DCTH
|
205.8m USD | -4.5 | ||
US |
Abbott Laboratories
NYSE:ABT
|
179.1B USD | 18.8 | ||
US |
Intuitive Surgical Inc
NASDAQ:ISRG
|
142B USD | 58.7 | ||
US |
Stryker Corp
NYSE:SYK
|
125.7B USD | 24.3 | ||
IE |
Medtronic PLC
NYSE:MDT
|
113.2B USD | 14.3 | ||
US |
Boston Scientific Corp
NYSE:BSX
|
111.5B USD | 31.7 | ||
US |
Becton Dickinson and Co
NYSE:BDX
|
68.2B USD | 18.1 | ||
DE |
Siemens Healthineers AG
XETRA:SHL
|
59.8B EUR | 18.4 | ||
US |
Edwards Lifesciences Corp
NYSE:EW
|
54.2B USD | 27.9 | ||
US |
Dexcom Inc
NASDAQ:DXCM
|
51.9B USD | 60.6 | ||
CN |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
369.4B CNY | 27.9 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.